Global Sodium Iodide (131I) Capsules Market Research Report 2026: Industry Size, Competitive Landscape and Future Investment Outlook

Sodium Iodide (131I) Capsules - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
Global Leading Market Research Publisher QYResearch announces the release of its latest report “Sodium Iodide (131I) Capsules - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current market conditions, historical performance analysis from 2021 to 2025, and forecast calculations covering 2026 to 2032, this report delivers a comprehensive evaluation of the global Sodium Iodide (131I) Capsules market, including market size, market share, demand trends, competitive landscape, industry development status, and future growth opportunities.

The global Sodium Iodide (131I) Capsules market was estimated to be worth US$ million in 2025 and is projected to reach US$ million by 2032, expanding at a CAGR of % during the forecast period from 2026 to 2032. Driven by the increasing prevalence of thyroid-related diseases, expanding applications of nuclear medicine, and continuous advancements in radiopharmaceutical manufacturing technologies, Sodium Iodide (131I) Capsules are becoming an increasingly important segment within the global healthcare and nuclear medicine industry.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
[https://www.qyresearch.com/reports/5735628/sodium-iodide--131i--capsules]

Market Overview and Product Definition
Sodium Iodide (131I) Capsules are specialized radiopharmaceutical products containing radioactive iodine-131, primarily used for the diagnosis and treatment of thyroid disorders. As a clinically established isotope-based medicine, Iodine-131 has played a critical role in nuclear medicine for decades due to its unique ability to selectively accumulate in thyroid tissue.

Iodine-131 (131I, I-131) is a radioactive isotope of iodine originally discovered in 1938 by Glenn Seaborg and John Livingood at the University of California, Berkeley. With a radioactive half-life of approximately eight days, I-131 provides sufficient therapeutic effectiveness while allowing controlled radioactive decay after administration.

The product is widely utilized in thyroid disease management, especially for radioactive iodine therapy in hyperthyroidism treatment and thyroid cancer ablation procedures. Compared with traditional treatment approaches, Sodium Iodide (131I) Capsules provide targeted radiation delivery, enabling physicians to achieve therapeutic outcomes with relatively precise control of radioactive exposure.

From a commercial perspective, Sodium Iodide (131I) Capsules represent a highly specialized pharmaceutical category with significant technical barriers. Manufacturing requires strict compliance with nuclear safety regulations, isotope production capabilities, quality control systems, and specialized distribution networks. These characteristics create a market structure with relatively high entry barriers and strong competitive advantages for established radiopharmaceutical companies.

Global Market Size and Growth Analysis
According to QYResearch market analysis, the global Sodium Iodide (131I) Capsules market is expected to experience steady expansion between 2026 and 2032. The market growth is supported by multiple long-term healthcare trends, including the rising global incidence of thyroid cancer, increasing diagnosis rates of thyroid disorders, and broader adoption of nuclear medicine technologies.

The growing burden of thyroid diseases has become a major factor supporting market demand. Hyperthyroidism remains one of the most common endocrine disorders worldwide, while differentiated thyroid cancer continues to represent one of the most frequently diagnosed endocrine malignancies. As healthcare systems improve early diagnosis capabilities and increase access to specialized treatments, demand for radioactive iodine-based therapies is expected to maintain stable growth.

In addition, improvements in radiopharmaceutical supply chains and hospital nuclear medicine infrastructure are strengthening market development. Many countries are increasing investment in nuclear medicine facilities, isotope production capabilities, and advanced therapeutic solutions, creating additional opportunities for manufacturers of Sodium Iodide (131I) Capsules.

Key Characteristics Driving Industry Development
1. Increasing Demand for Nuclear Medicine-Based Treatment Solutions
One of the primary characteristics of the Sodium Iodide (131I) Capsules industry is the continued expansion of nuclear medicine applications. Unlike conventional pharmaceutical products, radiopharmaceuticals combine pharmaceutical science with nuclear technology, offering highly targeted diagnostic and therapeutic capabilities.

The growing acceptance of personalized medicine and precision treatment approaches is further encouraging the adoption of radioactive iodine therapy. Hospitals and healthcare providers are increasingly focusing on treatment solutions that provide effective disease management while reducing unnecessary exposure and improving patient outcomes.

2. High Technical and Regulatory Barriers
The Sodium Iodide (131I) Capsules market is characterized by strict regulatory requirements and complex manufacturing processes. Companies operating in this sector must comply with radiation safety standards, pharmaceutical quality regulations, and government licensing requirements.

The short half-life of iodine-131 also creates unique supply chain challenges. Manufacturers must maintain reliable production schedules, efficient logistics systems, and regional distribution capabilities to ensure product availability.

These barriers contribute to a concentrated competitive environment where established manufacturers with technological expertise and regulatory experience maintain strong market positions.

3. Growing Focus on Global Radiopharmaceutical Supply Security
Recent developments in healthcare infrastructure have increased attention toward securing stable isotope supplies. Governments, hospitals, and pharmaceutical companies are investing in strengthening domestic and regional radiopharmaceutical production capabilities.

The strategic importance of isotope availability has encouraged manufacturers to expand production capacity, improve manufacturing efficiency, and establish stronger partnerships across the nuclear medicine ecosystem.

4. Expansion of Emerging Healthcare Markets
While North America and Europe have historically represented important markets for nuclear medicine applications, emerging economies in Asia-Pacific and other regions are creating new growth opportunities.

Increasing healthcare expenditure, improving hospital infrastructure, and rising awareness of advanced thyroid disease treatments are accelerating market expansion in developing regions. Countries investing in nuclear medicine facilities are expected to become increasingly important contributors to future demand.

Competitive Landscape and Major Manufacturers
The global Sodium Iodide (131I) Capsules market includes several internationally recognized radiopharmaceutical companies with established production capabilities and distribution networks.

The major manufacturers analyzed in the report include:

Jubilant Radiopharma

ANSTO

Beijing Atom High-Tech

PDRadiopharma

Curium Pharma

NTP Radioisotopes

These companies compete through product quality, regulatory compliance, manufacturing capacity, regional availability, and technological capabilities.

Leading market participants are focusing on expanding radiopharmaceutical portfolios, improving isotope production efficiency, strengthening healthcare partnerships, and developing reliable supply chains. Strategic investments in production infrastructure and international cooperation are expected to remain important competitive strategies during the forecast period.

Market Segmentation Analysis
The Sodium Iodide (131I) Capsules market is segmented based on product type and application.

Segment by Type
Therapy Capsules

Therapy capsules represent one of the most important product categories, primarily used for radioactive iodine treatment of thyroid diseases. These products are designed to deliver therapeutic radiation doses to thyroid tissues and are widely used in hyperthyroidism management and thyroid cancer treatment.

Diagnostic Capsules

Diagnostic capsules are used for thyroid function assessment, radioactive iodine uptake studies, and disease evaluation. Growing demand for accurate thyroid diagnostics is supporting the continued development of this segment.

Segment by Application
Hyperthyroidism

Hyperthyroidism treatment remains a major application area for Sodium Iodide (131I) Capsules. Radioactive iodine therapy is widely recognized as an effective treatment option due to its ability to selectively target thyroid cells.

Thyroid Cancer

The increasing incidence of thyroid cancer and the growing adoption of radioactive iodine ablation therapy are expected to generate additional market opportunities. Thyroid cancer treatment applications represent a strategically important growth area for manufacturers.

Future Market Outlook 2026-2032
Looking ahead, the Sodium Iodide (131I) Capsules market is expected to benefit from sustained healthcare demand, technological innovation, and increasing global investment in nuclear medicine.

Future industry development will likely focus on improving production efficiency, enhancing supply chain reliability, and expanding access to advanced radiopharmaceutical treatments. Companies capable of combining regulatory expertise, manufacturing strength, and global distribution capabilities will be better positioned to capture emerging opportunities.

For investors, pharmaceutical companies, healthcare organizations, and industry decision-makers, Sodium Iodide (131I) Capsules represent a specialized but strategically valuable market segment within the broader radiopharmaceutical industry.

As thyroid disease diagnosis and treatment continue to evolve globally, radioactive iodine-based therapies are expected to maintain an essential role in modern nuclear medicine, supporting long-term market development through 2032.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:

QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp